We previously identified NMRK2 as a direct target of TFE3 fusion proteins; however, effective drugs targeting NMRK2 are lacking.[14, 22] Further exploration of other TFE3 target genes involved in TFE3‐RCC progression is necessary. The gene discussed is NMRK2; the disease is renal cell carcinoma.